Austedo XR: FDA Approved for Tardive Dyskinesia

In a significant advancement for those suffering from tardive dyskinesia (TD), the U.S. Food and Drug Administration (FDA) recently approved Austedo XR (extended-release deutetrabenazine). This approval brings a new, convenient treatment option for patients grappling with this often debilitating condition.
The most notable advantage of Austedo XR is its once-daily dosing regimen. This is a significant improvement over the immediate-release form, which requires twice-daily dosing. A once-daily pill is easier for patients to adhere to, improving overall treatment compliance.
Read blog post here: psychiatryeduc...